BillionToOne denies allegations in a report from Fuzzy Panda Research, asserting inaccuracies and maintaining confidence in its business practices.
Quiver AI Summary
BillionToOne, Inc., a molecular diagnostics company based in Menlo Park, has issued a response to a report released by Fuzzy Panda Research, a short seller with a vested interest in reducing the company's stock value. BillionToOne asserts that the report contains many inaccurate and misleading claims, relying on anonymous sources and selective data. The company emphasizes its commitment to transparency, the integrity of its business practices, and the clinical validity of its tests, stating that it adheres to healthcare compliance regulations. CEO Dr. Oguzhan Atay expressed pride in the company's mission and commitment to its patients and shareholders. BillionToOne is currently consulting with legal advisors regarding the report and considering its options.
Potential Positives
- BillionToOne strongly defends its business practices and the quality of its tests against potentially damaging claims, demonstrating confidence in its integrity and commitment to accuracy.
- The company emphasizes its comprehensive healthcare compliance program and adherence to laws and regulations, reinforcing its credibility in the healthcare sector.
- Management plans to consult with legal advisors regarding the report, indicating a proactive approach to protecting the company's reputation and shareholder interests.
- The CEO publicly reaffirms the company’s mission and dedication to patients, which can resonate positively with clinicians, families, and investors alike.
Potential Negatives
- The response to the Fuzzy Panda Research report indicates that investors may have significant concerns regarding the integrity and credibility of BillionToOne's business practices, which could negatively impact investor confidence.
- The issuance of a statement addressing a negative report from a short seller may suggest that the company is facing serious allegations that could lead to further scrutiny or regulatory inquiries.
- The need to review the report with legal advisors implies potential legal risks that could arise from the claims made, creating uncertainty regarding the company's future operations and financial stability.
FAQ
What did BillionToOne say about the Fuzzy Panda Research report?
BillionToOne categorically rejects the report, stating it contains numerous inaccurate and misleading claims.
How does BillionToOne ensure compliance with regulations?
The company maintains a comprehensive healthcare compliance program and follows applicable laws regarding billing and financial practices.
What is the mission of BillionToOne?
BillionToOne aims to create powerful and accurate molecular diagnostic tests that are accessible to all.
What technology does BillionToOne use for its tests?
The company uses its patented Quantitative Counting Templates™ (QCT™) platform, which counts DNA molecules at the single-molecule level.
Who can be contacted for more information about BillionToOne?
For inquiries, contact their Investor Relations at [email protected] or Media Relations at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BLLN Insider Trading Activity
$BLLN insiders have traded $BLLN stock on the open market 212 times in the past 6 months. Of those trades, 0 have been purchases and 212 have been sales.
Here’s a breakdown of recent trading of $BLLN stock by insiders over the last 6 months:
- OGUZHAN ATAY (Chairman and CEO) has made 0 purchases and 108 sales selling 263,538 shares for an estimated $30,500,442.
- DAVID TSAO (Chief Technology Officer) has made 0 purchases and 51 sales selling 123,333 shares for an estimated $13,211,452.
- THOMAS P. LYNCH (See Remarks) has made 0 purchases and 17 sales selling 55,112 shares for an estimated $5,873,845.
- NANCY JOANN JOHNSON (See Remarks) has made 0 purchases and 12 sales selling 29,000 shares for an estimated $3,324,223.
- SHAN RIKU SAKAKIBARA (Chief Product Officer) has made 0 purchases and 9 sales selling 24,000 shares for an estimated $2,665,800.
- BOSCH JOHN RODERICK TEN (SVP of Laboratory Operations) has made 0 purchases and 15 sales selling 21,249 shares for an estimated $2,341,611.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BLLN Hedge Fund Activity
We have seen 118 institutional investors add shares of $BLLN stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 604,957 shares (+650.8%) to their portfolio in Q3 2026, for an estimated $64,391,623
- INVESCO LTD. added 547,856 shares (+65.6%) to their portfolio in Q3 2026, for an estimated $58,313,792
- NVP ASSOCIATES, LLC removed 513,330 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $61,589,333
- DEEP TRACK CAPITAL, LP added 500,000 shares (+inf%) to their portfolio in Q3 2026, for an estimated $53,220,000
- FULLER & THALER ASSET MANAGEMENT, INC. removed 418,565 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $44,552,058
- NEUBERGER BERMAN GROUP LLC removed 410,584 shares (-53.7%) from their portfolio in Q3 2026, for an estimated $43,702,560
- BLACKROCK, INC. added 331,803 shares (+290.3%) to their portfolio in Q3 2026, for an estimated $35,317,111
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BLLN Analyst Ratings
Wall Street analysts have issued reports on $BLLN in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/10/2026
- JP Morgan issued a "Overweight" rating on 11/05/2026
- BTIG issued a "Buy" rating on 11/05/2026
- Guggenheim issued a "Buy" rating on 10/01/2026
- Canaccord Genuity issued a "Buy" rating on 09/02/2026
To track analyst ratings and price targets for $BLLN, check out Quiver Quantitative's $BLLN forecast page.
$BLLN Price Targets
Multiple analysts have issued price targets for $BLLN recently. We have seen 5 analysts offer price targets for $BLLN in the last 6 months, with a median target of $130.0.
Here are some recent targets:
- David Westenberg from Piper Sandler set a target price of $130.0 on 11/10/2026
- Casey Woodring from JP Morgan set a target price of $135.0 on 11/05/2026
- Mark Massaro from BTIG set a target price of $130.0 on 11/05/2026
- Subbu Nambi from Guggenheim set a target price of $128.0 on 10/01/2026
- Kyle Mikson from Canaccord Genuity set a target price of $120.0 on 09/02/2026
Full Release
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company today responded to a report published on November 18, 2026 by Fuzzy Panda Research, a short seller that, by its own disclosure, holds a short position in BillionToOne securities and stands to profit from driving down the company’s stock price.
BillionToOne believes the report contains numerous inaccurate, distorted, unsupported, and highly misleading claims. The report relies heavily on anonymous sources, selectively presented data, and speculative extrapolation to reach conclusions that BillionToOne categorically rejects.
BillionToOne stands behind the integrity of its business practices, the quality and clinical validity of its tests, and the accuracy of its public disclosures. The Company maintains a comprehensive healthcare compliance program, and its billing, patient financial assistance, and commercial practices comply with applicable laws and regulations. BillionToOne is committed to transparent disclosure, and its filings with the Securities and Exchange Commission are accurate and complete in all material respects.
BillionToOne is reviewing the report with its legal advisors to consider all available legal options.
“Every day, clinicians and families rely on BillionToOne’s tests at some of the most consequential moments of their care, and we take that responsibility seriously,” said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne. “We built this company on rigorous science, transparency, and doing right by patients. I am proud of our team, and we remain focused on delivering for the patients, providers and shareholders who count on us.”
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding BillionToOne’s business, financial outlook and evaluation of legal options. Words such as “believe,” “expect,” “intend,” “plan,” “may,” “will” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks relating to the report and any resulting litigation, regulatory inquiry or reputational harm and the risks described under “Risk Factors” in BillionToOne’s most recent Quarterly Report on Form 10-Q, its Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release, and BillionToOne undertakes no obligation to update them except as required by law.
Investor Contact
[email protected]
Media Contact
[email protected]